Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo

Author(s): Jagdish K. Sahu* and Arun K. Mishra

Volume 16, Issue 3, 2019

Page: [259 - 264] Pages: 6

DOI: 10.2174/1570163815666180502165014

Price: $65

Abstract

Objective: Ozenoxacin is one of the potent quinolone antibiotics, recently approved by the United States Food and Drug Administration (USFDA) with reported pharmacology to treat the impetigo. The demand for better acting topical formulation is increasing day by day. The present review is an attempt to summarize the facts behind the chemistry and biological applications of Ozenoxacin.

Mechanism of Action: This novel drug being a quinolone antibiotic compound, acts by inhibiting DNA gyrase A and topoisomerase IV and affects supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and many others.

Pharmacology: Ozenoxacin has demonstrated to have a bactericidal activity against organisms, such as Staphylococcus aureus and Staphylococcus pyogenes. Ozenoxacin is non-fluorinated quinolone and being developed for the other dermatological bacterial infections as well. No sign of genotoxicity was observed when tested experimentally.

Conclusion: The present review also covers the complete picture of pharmacokinetics, clinical trials, toxicity and future scope and possible avenues in this arena.

Keywords: Impetigo, Ozenoxacin, Staphylococcus aureus, Staphylococcus pyogenes, quinolone antibiotic, drug discovery.

Graphical Abstract

[1]
McCormick A, Fleming D, Charlton J. Morbidity statistics from general practice Fourth national study 1991-1992. London: HMSO 1995.
[2]
Tilbury Fox W. On impetigo contagiosa, or porrigo. BMJ 1864; i: 467-9.
[3]
Public Health Laboratory Service. ‘Wired for health’: Impetigo. Factsheet for schools. 1999 URL.www.phls.co.uk/facts/ wfhfactsheets/WFHimpetigo.htm (Accessed 10 April 2002).
[4]
Sewell DL. Bacteriology In: McClatchey KD (ed) Clinical laboratory medicine Baltimore: Williams and Wilkins 1994; pp.1111-1168.
[5]
Infections of skin and soft tissue In: Inglis TJJ (ed) Microbiology and infection Edinburgh: Churchill Livingstone 1996; pp. 51-62.
[6]
Darmstadt GL, Lane AT. Impetigo: An overview. Pediatr Dermatol 1994; 11: 293-303.
[7]
Dagan R. Impetigo in childhood: changing epidemiology and new treatments. Pediatr Ann 1993; 22: 235-40.
[8]
https://www.outsourcedpharma.com/doc/ferrer-successfully-completes-a-phase-iii-clinical-trial-in-adult-0001 (Accessed on 30/12/2017).
[9]
Nakajima A, Ikeda F, Kanayama S, et al. Antimicrobial activities of ozenoxacin against the isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris. J Med Microbiol 2016; 65: 745-50.
[10]
Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: An update. Int J Dermatol 2003; 42: 251-5.
[11]
Tato M, López Y, Morosini MI, et al. Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values. Diagn Microbiol Infect Dis 2014; 78: 263-7.
[12]
Hayashi N, Akamatsu H, Iwatsuki K, et al. Guidelines for the treatment of acne vulgaris 2016. Jpn J Dermatol 2016; 126: 1045-86.
[13]
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
[14]
Craig WA, Gudmundsson S. Postantibiotic effect In: Lorian V, editor Antibiotics in laboratory medicine 4th ed 1996; pp. 296- 329.
[15]
Andes D, Craig WA. Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother 2003; 47: 3935-41.
[16]
Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002; 46: 1665-70.
[17]
Filocamo A, Bisignano C, D’Arrigo M, Ginestra G, Mandalari G, Galati EM. Norfloxacin and ursolic acid: In vitro association and postantibiotic effect against Staphylococcus aureus. Lett Appl Microbiol 2011; 53: 193-7.
[18]
López Y, Tato M, Espinal P, et al. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. Antimicrob Agents Chemother 2013; 57(12): 6389-92.
[19]
Fabrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb Biotechnol 2009; 2(1): 40-61.
[20]
Laponogov , et al. Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases. Nature Struct & Molec Biol 2009; 16(6): 667.
[21]
http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=373399 (Accessed on 30/12/2017).
[22]
http://www.chemicalbook.com/ChemicalProductProperty_EN_CB62498834.htm (Accessed on 30/12/2017).
[23]
https://www.pharmacodia.com/web/drug/1_666.htmlaccessed on 05/01/2018.
[24]
Yamakawa T, Mitsuyama J, Yamashiro Y. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother 2002; 49: 455-65.

Rights & Permissions Print Cite
Article Metrics
49
3
© 2024 Bentham Science Publishers | Privacy Policy